Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Korea SE
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Generic Pharma

Shin Poong Pharmaceutical Co Ltd

+ Add to Watchlist

019170:KS

4,310 KRW 15 0.35%

As of 01:23:01 ET on 02/27/2015.

Snapshot for Shin Poong Pharmaceutical Co Ltd (019170)

Open: 4,300 Day's Range: 4,265 - 4,355 Volume: 73,990
Previous Close: 4,325 52wk Range: 3,654 - 4,808 1-Yr Rtn: -5.63%

Stock Chart for 019170

No chart data available.
  • 019170:KS 4,310
  • 1D
  • 1M
  • 1Y
4,325
Interactive 019170 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for 019170

Current P/E Ratio (ttm) 33.4510
Estimated P/E(12/2014) -
Relative P/E vs. KOSPI 1.1372
Earnings Per Share (KRW) (ttm) 128.8452
Est. EPS (KRW) (12/2014) -
Est. PEG Ratio -
Market Cap (M KRW) 194,889.58
Shares Outstanding (M) 45.22
30 Day Average Volume 47,786
Price/Book (mrq) 0.9163
Price/Sale (ttm) 0.7687
Dividend Indicated Gross Yield 0.86%
Cash Dividend (KRW) 36.9819
Dividend Ex-Date 12/27/2013
5 Year Dividend Growth -
Next Earnings Announcement 03/05/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for 019170

No data available

Company Profile & Key Executives for 019170

Shin Poong Pharmaceutical Co., Ltd. manufactures pharmaceutical raw materials and prescription drugs, such as cephalosporin antibiotics, hemostatics, sedative agents, and anti-diabetics.

Ryu Jei-ManRep DirectorKim Byeong-YongExecutive Director
More Company Profile & Key Executives for 019170

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil